Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RGS3 antisense RNA 1 (RGS3-AS1)
- Target
- RGS3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
RGS3 antisense RNA 1 (RGS3-AS1) is a long non-coding RNA (lncRNA) transcribed in the antisense direction relative to the RGS3 gene. Antisense lncRNAs like RGS3-AS1 often regulate the expression or splicing of their sense counterparts, although the specific biological role of RGS3-AS1 has not been well characterized in published studies. While its related sense gene, RGS3, is a GTPase-activating protein involved in G-protein signaling and is implicated in cancer progression and cell signaling pathways such as TGF-β[1][3], there are no direct functional or disease associations described for RGS3-AS1. Antisense lncRNAs typically act by RNA-RNA duplex formation, transcriptional interference, or chromatin modification but further characterization is needed for RGS3-AS1 specifically[2]. If a more precise functional or disease role for RGS3-AS1 becomes available in future research, these categories should be updated accordingly.
- Other names
- RGS3-AS1
02
Mechanism of action
Not applicable. Since RGS3-AS1 is not a drug target, mechanisms of action for drugs are not available.
03
Biological functions
Likely to participate in gene regulation through antisense transcript mechanisms, including regulation of RGS3 gene expressionOther specific functions for RGS3-AS1 are not well characterized in literature; its family (lncRNA/antisense RNA) is typically involved in transcriptional or post-transcriptional regulation
04
Disease associations
Unknown. There is currently no evidence linking RGS3-AS1 directly to disease processes, although its corresponding sense gene RGS3 is implicated in cancer biology and signaling pathways[1][3]
05
Safety considerations
None reported. As a non-coding RNA, there are no direct therapeutic or safety issues associated.
06
Interacting drugs
None identified. No drugs are reported to specifically interact with RGS3-AS1.
07
Biomarkers
None known. RGS3-AS1 is not reported as a biomarker for selection or monitoring.
Beyond the preview
Go deeper on RGS3 antisense RNA 1 (RGS3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGS3 antisense RNA 1 (RGS3-AS1).